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A Structural Basis for the Selection of Dominant
 T Cell Receptors in Antiviral Immunity
number of nucleotides at the VDJ junctional sites, called
N-regions. The residual repertoire of unique TCRs fol-
lowing thymic selection is between 107 and 108 (Arstila et
Lars Kjer-Nielsen,1,5 Craig S. Clements,2,5
Anthony W. Purcell,1 Andrew G. Brooks,1
James C. Whisstock,2,3 Scott R. Burrows,4
al., 1999). Despite this vast potential repertoire, immuneJames McCluskey,1,*,6 and Jamie Rossjohn2,*,6
responses often show strong unexplained biases in TCR1Department of Microbiology & Immunology
selection, resulting in immunodominance of certainUniversity of Melbourne
“public” TCRs that are widely used in individuals withParkville
shared MHC types (Acha-Orbea et al., 1988; JorgensenVictoria 3010
et al., 1992; Tomonari, 1992; Argaet et al., 1994; Burrows2 The Protein Crystallography Unit
et al., 1995; Callan et al., 1995; Sim et al., 1996; Torres-Department of Biochemistry and Molecular Biology
Nagel et al., 1997; Callan et al., 1998; Wilson et al., 1998;School of Biomedical Sciences
Annels et al., 2000; Bourcier et al., 2001).3 Victorian Bioinformatics Consortium
Although recent structural studies have revealedMonash University
much about the nature of TCR interactions with MHCp,Clayton
there are little data on the structural properties of publicVictoria 3168
or dominant  clonotypes, that might account for their4 Queensland Institute of Medical Research
preferential selection in immune responses. In contrastThe Bancroft Centre
to  TCRs,  TCR gene usage is generally very re-Herston 4029
stricted (Carding and Egan, 2002), and in those  T cellsQueensland
that are adapted to recognize phosphorylated antigens,Australia
the preferential use of the V9 and V2 gene segments
appears to reflect the structural specificity of the recep-
tor (Allison et al., 2001). However,T cell antigen recep-Summary
tors can directly recognize intact antigens, as distinct
from  TCRs that recognize peptides complexed withWe have examined the basis for immunodominant or
polymorphic MHC molecules. Thus, the mechanism(s)“public” TCR usage in an antiviral CTL response. Resi-
of immunodominance in  TCR usage is less clear.dues encoded by each of the highly selected genetic
The first and second complementarity determiningelements of an immunodominant clonotype recogniz-
regions (CDRs) of the  TCR are encoded within theing Epstein-Barr virus were critical to the antigen
V and V genes, whereas the CDR3 regions are derivedspecificity of the receptor. Upon recognizing antigen,
from the V-(D)-J and N-regions. With some exceptionsthe immunodominant TCR undergoes extensive con-
(Reiser et al., 2000), the emerging paradigm for TCRformational changes in the complementarity determin-
interaction with MHCp suggests a common diagonal
ing regions (CDRs), including the disruption of the ca-
docking mode, whereby the CDR1 and CDR2 loops con-
nonical structures of the germline-encoded CDR1
tact the MHC  helices of the antigen binding groove,
and CDR2 loops to produce an enhanced fit with the while the more diverse CDR3  and  loops interact
HLA-peptide complex. TCR ligation induces confor- primarily with the peptide (Garboczi and Biddison, 1999;
mational changes in the TCR constant domain Garcia et al., 1999; Hennecke and Wiley, 2001). Large
thought to form part of the docking site for CD3. conformational changes in some of these CDR loops
These findings indicate that TCR immunodominance have also been observed upon binding (Garcia et al.,
is associated with structural properties conferring re- 1998; Reiser et al., 2002), where non-rigid body shifts
ceptor specificity and suggest a novel structural link are restricted to the CDR3 loops, analogous to antibody-
between TCR ligation and intracellular signaling. antigen interactions. However, there is no structural
evidence for a ligand-induced conformational switch
Introduction translating TCR ligation to the signaling apparatus.
We have examined the structural features of a highly
T cells bearing specific  receptors (TCRs) recognize immunodominant CTL response that arises naturally in
antigenic peptide complexes presented by HLA mole- immunity to Epstein-Barr virus (EBV), a human pathogen
cules of the major histocompatibility complex (MHCp) that causes a persistent infection in about 90% of adults
(Davis and Bjorkman, 1988). The specificity of clonally (Moss et al., 2001). Unrelated individuals with the MHC
distributed TCRs is diversified through the random re- class I molecule HLA-B8 virtually all make an immuno-
arrangement of V and J genes at the TCR locus and dominant CTL response to the peptide FLRGRAYGL
from the latent antigen EBNA 3A (Argaet et al., 1994;V, D, and J genes at the TCR locus of developing
Callan et al., 1998). Remarkably, these CTL nearly allthymic T cells. Further potential diversity is created
use the same TCR and - chains derived from identicalthrough untemplated addition or deletion of a variable
V, J (TRAV26-2*01; TRAJ52*01), and N-region se-
quences; and identical TCR V, D, J (TRBV7-8*03;*Correspondence: jamesm1@unimelb.edu.au (J.M.), jamie.rossjohn@
TRBD1/D2; TRBJ2-7*01) (Lefranc, 2001), and N-regionmed.monash.edu.au (J.R.)
sequences (Argaet et al., 1994; Callan et al., 1998). A5 These authors contributed equally to this work.
6 These authors contributed equally to this work. CTL clone, LC13 (Argaet et al., 1994), represents a proto-
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et al., 1998); A6/HLA-A2-Tax, 1980 A˚2 (Ding et al., 1998,Table 1. Data Collection and Refinement Statistics
1999); BM3.3/H-2Kb-pBM1, 1360 A˚2 (Reiser et al., 2000);
Data Collection Statistics 2C/H-2Kb/bm3-SIYR, 1840 A˚2 (Garcia, et al., 1996, 1998;
Luz et al., 2002); KB5-C20, 1800 A˚2 (Reiser et al., 2002);Temperature 100 K
X-ray source APS, Biocars 14-BMC perhaps reflecting an important feature of this immuno-
Detector Quantum 4 CCD dominant receptor. Markedly different V and V involve-
Space Group P212121 ment has been observed at the MHC interface of some
Cell dimensions (A˚) (a,b,c) 56.49 105.90 144.52
receptors with the human A6/HLA A2-Tax (Y8A) adopt-Resolution (A˚) 2.5
ing one extreme (V 74%; V 26%) (Figure 2B) and theTotal number observations 77349
BM3.3/H-2Kb-pBM1 complex adopting the other (VNumber unique observations 29027
Multiplicity 2.7 37%; V 63%). In the LC13/HLA-B8/FLRGRAYGL com-
Data completeness (%) 92.9 (95.0) plex, there is roughly equivalent usage of the variable
Number data  2I 63 (42) domains (V 58%; V 42%) at the interface, consistent
I/I 12.1 (2.4) with specificity-driven selection of both public  and 
Rmergea (%) 9.1 (45.1)
chain TCR sequences (Figure 2A). There is one salt
Refinement Statistics bridge at the interface (CDR2-Glu 52 with HLA-B8-Arg
79), 14 hydrogen bonds, four water-mediated hydrogenNon hydrogen atoms
Protein 6616 bonds, and a multitude of nonpolar interactions (Table
Water 255 2). All the CDR loops contribute to these interactions,
Resolution (A˚) 50 - 2.5 albeit to a differing degree, consistent with multiple
Rfactorb (%) 22.6 specificity contributions derived from different genetic
Rfreec (%) 28.8 elements of the immunodominant receptor. Like the A6Rms deviations from ideality
and B7 human TCRs, CDR1 is minimally involved (4%)Bond lengths (A˚) 0.008
in contacting HLA-B8/FLRGRAYGL; CDR1, CDR2,Bond angles () 1.44
Dihedrals () 25.9 and CDR2 all contribute equally (17%) to the interface
Impropers () 0.88 and fall within the range observed for other TCRs (Ru-
Ramachandran plot dolph and Wilson, 2002) (Figures 2A and 2B).
Most favored and allowed region (%) 98.6
Despite having similar buried surface areas on com-B factors (A˚2)
plexation, CDR2 is involved in a much greater numberAverage main chain 39.1
of interactions than CDR2, and these are in a localizedAverage side chain 40.1
Average water molecule 35.1 stretch that spans residues 72–79 of the 1 helix of HLA-
Rms deviation bonded Bs 1.58 B8 (Figure 1B and Table 2). Of the 54 V genes and
alleles, the sequence of residues comprising CDR2The LC13/HLA-B8/FLRGRAYGL complex crystallizes in space
is unique to TRBV7-8 and TRBV7-9, suggesting thatgroup P212121, with a single complex per asymmetric unit. The struc-
ture of the complex was determined to 2.5 A˚ resolution to an Rfac selection of the V7-8 segment in LC13 (Lefranc, 2001)
and Rfree of 22.6% and 28.8%, respectively. The electron density for is based on its ligand specificity.
all domains of the complex as well as at the TCR/MHC interface The centrally located CDR3 and CDR3 regions, en-
was unambiguous. The values in parentheses are for the highest
coded by the V-(DN)-J-N junctions, also contributeresolution bin (approximate interval 0.1 A˚).
roughly equally at the interface (24% and 21%, respec-a Rmerge  	 |Ihkl 
 Ihkl|/	Ihkl
tively), although they display quite different roles withb Rfactor  	hkl||Fo| 
 |Fc||/	hkl|Fo|
c Rfree  5% of the data used for this calculation CDR3 dominating in MHCp contacts (Figure 1C and
Table 2). The peptide contributes only 22% to the buried
surface area, with the majority of this contribution arising
from one residue, the P7 Tyrosine (Figures 1 and 2A).
type of this response, and we have solved the structure Within the framework of the common diagonal dock-
of this receptor complexed to its cognate ligand HLA- ing mode, TCRs have been seen to adopt differing posi-
B8/FLRGRAYGL and compared this to the recently de- tions at the MHC interface (Teng et al., 1998). The LC13
termined structures of its unliganded counterparts (Kjer- TCR is translated to the extreme C terminus of the MHC-
Nielsen et al., 2002a, 2002b). peptide binding groove, while still lying within the helical
peaks of the HLA molecule. The translational shift of the
Results LC13 TCR to the peptide C terminus is most apparent
when comparing LC13 with the human HLA A2-Tax com-
Overview of the Crystal Structure of the plexed with either the B7 or the A6 TCRs, where LC13
LC13/HLA-B8/FLRGRAYGL Complex is shifted by 14.4 A˚ and 14 A˚, respectively (Garboczi et
The statistics of the overall structure are described in al., 1996; Ding et al., 1998) (Figures 2A and 2B). As the
Table 1, and the structure is shown in Figure 1. With LC13 TCR complex described here is the first HLA-B-
respect to the long axis of the HLA-B8 peptide binding restricted complex to be solved, it is not possible to
groove, the LC13 TCR binds in an approximate diagonal determine whether the observed translational shift re-
mode (60) (Figure 2A), that falls within the range of flects a general difference in the pattern of TCR interac-
previously reported TCR/MHCp complexes. The total tion with HLA-A versus HLA-B. LC13 is most similar in
buried surface area (Lesk, 1986) upon complexation is position to the BM3.3/H-2Kb-pBM1 complex on the MHC
 2220 A˚2 (Figure 2A), which is notably higher than those (3.2 A˚ apart). The mode of LC13 interaction is consistent
TCR/class I MHCp interfaces whose crystal structures with the fine specificity of FLRGRAYGL substitution ana-
logs recognized by LC13 CTL (Figure 2C and Burrowshave been determined; B7/HLA-A2-Tax, 1870 A˚2 (Ding
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Figure 1. Overview of the LC13 T Cell Receptor Complexed to HLA-B8/FLRGRAYGL
(A) Ribbon representation of the LC13/HLA-B8/FLRGRAYGL complex. The  chain and  chain of LC13 TCR are shown in light red and blue,
respectively. The HLA-B8 heavy chain and the 2-microglobulin domain are shown in light and darker green, respectively. The bound EBV
peptide is in yellow, with the P7 Tyr residue shown in stick format.
(B) A close-up of the interface, in an orthogonal view to (A), with the CDR regions color coded CDR1, red; CDR2, magenta; CDR3, blue;
CDR1, orange; CDR2, green; and CDR3, cyan. Residues from CDR1 and CDR2 participating in polar contacts are highlighted.
(C) Involvement of the publicly encoded regions that encompass CDR3 at the interface. The CDR3 loop residues and their corresponding
amino acid sequence are color coded with the V backbone in red, N-region in dark blue, and J in dark green; CDR3 loop residues are
coded with the V backbone in orange; DN-region light blue and J light green. Residues P6 Ala, P7 Tyr, and P8 Gly of the FLRGRAYGL
peptide are shown in yellow. Part of the HLA-B8 2 helix has been removed to simplify the illustration. Selected residues from the HLA-B8
1 and 2 helices are shown in gray.
et al., 1995). Substitutions at P1 and P2 of FLRGRAYGL and 11 A˚ in depth and is surrounded by the loops of
CDR1, CDR3, and CDR3 encoded by the differentwere well tolerated for LC13 recognition consistent with
the absence of any TCR contacts with these N-terminal genetic components distinct to the LC13 receptor (Fig-
ures 1B, 2A, and 3). The main specificity interactionsresidues. In contrast, substitutions at P4, P6, P7, or
P8 dramatically impaired CTL recognition, reflecting the with the bound EBV peptide involve CDR1 and CDR3
(Table 2). The small residues of the FLRGRAYGL peptidefocus of the LC13 TCR on the C-terminal part of the
HLA-B8-peptide complex (Figure 2C). flanking the P7 Tyr (P6 Ala and P8 Gly, respectively)
enable the tyrosine to protrude deep within this pocketTranslational freedom in TCR docking suggests that
TCRs are able to scan along the peptide binding groove (Figure 1C), where it is sandwiched between two tyro-
sines, Tyr31 (CDR1) and Tyr100 (CDR3, J-derived)of a given MHCp surface prior to the final docking mode
being established, consistent with two-step binding for (Figures 3A and 3B), as well as making v.d.w. contacts
with Ala99 (N-region remodeled D) and Leu94T cell receptor recognition of MHCp (Wu et al., 2002).
(N-region) (Figure 3A). CDR3 makes only one v.d.w.
contact with the peptide (Leu94, an N-region residue)Dominant Roles for CDR1 and CDR3 in Mediating
TCR/-pMHC Interactions (Figure 3A), such that most of the direct contribution to
peptide specificity by TCR is made by Tyr31 fromThe P7 Tyr, which resides within a bulged and exposed
region of the EBV peptide, is clearly the pivotal residue CDR1 (Figure 3A).
Of the nine residues that comprise the CDR1 loop,for LC13 recognition. The focus of the LC13 TCR on this
C-terminal residue correlates well with its C-terminal four participate in MHCp interactions (Figures 1B and
3C and Table 2). The amino acid sequence of the LC13positioning on the HLA-B8 molecule (Figure 2A) and the
fine specificity of the LC13 CTL (Figure 2C). The P7 Tyr CDR1 is unique (TRAV26-2) (Lefranc, 2001), and the
cluster of residues making MHCp contacts Ser28, Gly29,occupies a centrally located TCR pocket 11 A˚ in length
Immunity
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Figure 2. Comparison of the LC13 TCR Footprint on the HLA-B8/FLRGRAYGL Complex with the Footprint of the A6/HLA-A2-Tax Complex
(A) LC13 footprint of the HLA-B8/FLRGRAYGL complex.
(B) A6 footprint of the HLA-A2-Tax complex. Color coding relates to atomic contacts. CDR regions are color coded CDR1, red; 2, magenta;
and 3, blue; CDR2, green; and 3, cyan. The peptide is shown in yellow for both complexes. The hypervariable region 4 interaction is shown
in gray for the A6/HLA-A2-Tax structure.
(C) Fine specificity analysis of LC13 CTL reactivity on peptide analogs. The fine specificity of the LC13 CTL was determined by systematically
substituting each residue in the FLRGRAYGL peptide with the remaining 19 genetically encoded amino acids (single letter amino acid code
shown) and then assaying their recognition by LC13 CTL in a standard cytotoxicity assay over a range of peptide concentrations (Burrows
et al., 1997a). The amino acid substitutions are shown on the horizontal axis and the molar concentration of peptide analog that gave 50%
maximum lysis for each substitution is shown on the vertical axis.
Thr30, and Tyr31 are not found in this combination in V domain is based on the critical specificity properties
contributed by this component of the receptor.any other V gene even though these residues do occur
individually at these positions in some V segments TCR recognition of the FLRGRAYGL peptide is also
very sensitive to substitutions at P6 Ala and P8 Gly(Lefranc, 2001). These MHCp interactions are discontin-
uous, forming contact sites with the peptide at P7 Tyr (Figure 2C). The majority of the contacts with P6 to P8
arise from the unique CDR3 loop and involve residues(Figure 3A), Arg62 of the 1 helix (Figure 3C), and resi-
dues 151–158 of the 2 helix (Figures 1B, 2A, and 3B Gln98 and Ala99, derived from complete N-region re-
modeling of one of the two D genes and residues fromand Table 2). These findings emphasize the variable role
of CDR1 (Correia-Neves et al., 2001, 1999), revising the intact J segment (Tyr100) (Figure 3A and Table 2).
Gln98 appears to be particularly important in controllingthe notion that the more “conserved nature” of the
CDR1 loop predominantly recognizes the MHC1 helix specificity in that this residue makes contact with the
HLA-B8 1 helix (Gln72, Thr73, and Glu76) (Figure 1C(Sim et al., 1996).
The base of the LC13 pocket comprises His33 and and Table 2) and P6 Ala of FLRGRAYGL (Figure 3A and
Table 2) while also making v.d.w. interactions withHis48 that form water-mediated hydrogen bonds to the
hydroxyl group of the Tyr7 (Figure 3A). The importance of Tyr100 of the V domain (Figure 1C [Tyr100 unlabeled
in green and Gln98 labeled in light blue] and Table 2).these hydrogen-bond interactions is verified by the 10-
fold loss of CTL recognition that occurs when P7 Tyr is The small side chains of Gly97 and Ala99 are encoded
by the DN-region and facilitate the flexibility of Gln98substituted by P7 Phe that lacks the hydroxyl group
involved in this bonding (Figure 2C). Moreover, His48 while permitting the P7 Tyr to protrude into the pocket
(Figure 3A).is unique to the TRAV 26-1 and 26-2 genes (Lefranc,
2001), further suggesting that selection of the TRAV 26-2 Tyr100 is only found in one other germline J seg-
Structural Basis of T Cell Receptor Immunodominance
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Table 2. Contacts at the TCR/MHC-P Interface and the Genetic Origin of TCR Residues
Number of TCR Gene
TCR MHC Type of Bond Contacts Segment
CDR1 Thr26O, Ser28O Arg62N2 Water-mediated 2 V
Ser28O Arg62N2 H bond 1 V
Tyr31O Arg151O H bond, vdw 5 V
Tyr31 Val152 Vdw 2 V
Tyr31 Gln155 8 V
Thr30O Gln155N2 H bond 4 V
Gly29 Ala158 Vdw 2 V
CDR2 His48N2 Ala150O H bond, vdw 2 V
Leu50N Glu54O1 Water-mediated 1 V
Leu50 Ala158 Vdw 1 V
CDR3 Leu94 Gln155 Vdw 1 V N-region
Gly96 Arg62, Ile66 4 J
Gly97 Ile66 Vdw 5 J
Gly97O Asn70O1 Water-mediated 1 J
Gly97O Thr69O1 H bond, vdw 4 J
Thr98O Thr69 H bond, vdw 3 J
Thr98 Gln65 Vdw 5 J
Ser99 Thr69 2 J
Tyr100 Gln72 Vdw 6 J
CDR1 Ser31 Glu76 Vdw 1 V
CDR2 Tyr48 Glu76, Gln72 Vdw 2 V
Gln50N2 Gln72O H bond 2 V
Glu76N
Arg75 Vdw 8
Asn51O1 Arg79N H bond, vdw 10 V
Glu52O2 Arg79N1, N2 Salt bridge, vdw 6 V
Leu55 Gln72 Vdw 2 V
CDR3 Leu96 Lys146 Vdw 2 V
Gly97 Glu76 Vdw 5 N-D
Gln98O1 Gln72N2 H bond, vdw 3 N-D
Gln98N2 Thr73O1 H bond, vdw 4 N-D
Gln98N Glu76O1 H bond, vdw 8 N-D
Tyr100 Lys146, Trp147, Ala150 Vdw 12 J
TCR/PEPTIDE Contacts
Leu94 (CDR3) Ala6 Vdw 8 V N-region
Ala99 (CDR3) Vdw N-D
Gln98 (CDR3) Vdw N-D
Gln98N2(CDR3) Ala6O H-bond N-D
Ala99 (CDR3) Tyr7 Vdw 12 N-D
Tyr31 (CDR1) V
Tyr100 (CDR3) J
His48, His33 Tyr7O Water-mediated 2 V
Tyr100O (CDR3) Gly8O H bond 1 J
ment and makes multiple interactions with HLA-B8 2 have determined the crystal structure of the unliganded
LC13 to 1.5 A˚ (Kjer-Nielsen et al., 2002b) and the unli-helix (Lys146, Trp147, and Ala150) (Figure 1C) as well
as P7 Tyr and P8 Gly of the FLRGRAYGL peptide (Fig- ganded HLA-B8/FLRGRAYGL complex to 1.9 A˚ (Kjer-
Nielsen et al., 2002a), allowing us to address the confor-ures 1C and 3A and Table 2).
The small P6 and P8 residues enable peptide back- mational changes that occur upon binding (Figure 3D).
A small rigid body shift was detected in the boundbone interactions to play a prominent role in interacting
with LC13: the main chain of P6 Ala hydrogen bonds peptide, and readjustment of the positions of some HLA-
B8 side chains maximize the interactions and shapeonto Gln98 (Figure 3A) and makes v.d.w. contacts with
Leu94, Ala99, and Gln98 (Figure 3A and Table 2). complementarity at the interface (Figure 3B). This is seen
most clearly in the HLA-B8 2 helix residue Gln155 thatThe main chain of the P8 Gly forms a hydrogen bond with
Tyr100 (Figure 3A). The structure reveals that particular forms a direct hydrogen bond with the P7 Tyr of the
FLRGRAYGL peptide in the unliganded state (Figureresidues encoded by different genetic segments of the
receptor genes appear to be selected for their direct spec- 3B, gray). However, upon TCR ligation, this residue is
displaced by Tyr31 and swings away to form a hydro-ificity roles in the binding of the HLA-B8/FLRGRAYGL
complex. gen bond with Thr30 of CDR1 (Figures 3B [yellow]
and 3C and Table 2). Thus an MHC residue devoted to
peptide binding prior to T cell recognition switches rolesInduced Fit at the LC13 Interface
Conformational plasticity of CDR regions appears to be to mediate TCR interaction upon T cell engagement.
Subtle domain movements between the unligandedan important property of TCRs that allows them to scan
and adapt to cognate MHCp interfaces. Previously, we and liganded TCR fell within the natural range of varia-
Immunity
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Figure 3. An Overview of the Conformational Changes between the Unliganded and Liganded LC13 TCR
(A) Conformational changes leading to enhanced ligand complementarity within the P7 Tyr binding pocket. CDR1, CDR3, and CDR3 are
shown in their unliganded (gray) and liganded (yellow) conformations. The liganded conformation of P6 Ala, P7 Tyr, and P8 Gly of the
FLRGRAYGL peptide is shown in green.
(B) Conformational changes that occur within the P7 Tyr binding pocket. The figure highlights the displacement of the HLA-B8 2 helix residue
Gln155 (Q155 in gray uncomplexed and yellow complexed) by the incoming residue Tyr31 (yellow complexed) of the CDR1 from the LC13
TCR.
(C) Ligation-dependent contacts between CDR1 and CDR3 are associated with enhanced HLA-B8 interaction. CDR1 and CDR3 are
shown in their unliganded (gray) and liganded (yellow) conformations. HLA-B8 1 and 2 helices are shown in green. P4-P8 of the FLRGRAYGL
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tion seen for TCRs (Wang et al., 1998). Four of the six of the LC13 TCR specificity. The Pro93 and Leu104
that mediate the crumpling of the CDR3 loop (FigureLC13 CDR loops (CDR 1, CDR 2, CDR3, and CDR3)
undergo marked conformational changes upon ligand 3A) are encoded by an N-region addition at the V-J
junction (Pro93) and a J residue (Leu104) (Figurebinding (Figure 3D). In the unliganded TCR crystal struc-
ture, although CDR3 is minimally involved in crystal 1C). Sequencing of cDNA from six HLA-B8-restricted,
FLRGRAYGL-specific CTL clones derived from five un-contacts (residues Leu96, Tyr100, and Glu105),
CDR1, CDR2, and CDR3 are not involved in crystal related donors revealed strict selection of these amino
acids despite the use of multiple codons encodingcontacts. These conformational changes at the interface
do not result in any change from the buried surface area Pro93 (Argaet et al., 1994). Thus, as well as the critical
specificity roles adopted by germline-encoded parts ofpredicted from modeling the docking of the receptor in
its unliganded structure. However, the conformational the LC13 TCR, somatically derived N-region residues
also exert a significant influence in specifying cognatechanges increase the shape complementarity index
(Lawrence and Colman, 1993) nearly 2-fold through ad- interactions.
justments that are controlled by residues encoded
within the unique genetic elements of the LC13 receptor Disruption of Canonicity Upon Ligand Binding
The existence of canonical CDR conformations in TCRsas discussed below.
Upon ligation, the CDR3 loop maximizes contacts with has been previously predicted (Al-Lazikani et al., 2000)
and confirmed with accumulated examples buildingthe FLRGRAYGL peptide. The conformational changes in
CDR3 involve a 2.5 A˚ rigid body shift (residues 97–100) upon the concept (Garcia et al., 1999; Reiser et al., 2000,
2002; Machius et al., 2001). The emerging view is thatwith a 38 rotation that allows the J-encoded Tyr100
to move down by approximately 5 A˚ to engage the like antibody hypervariable loops (Chothia and Lesk,
1987), the canonicity of a given CDR loop is inherentlyFLRGRAYGL-P7 Tyr (Figure 3A) and P8 Gly (Figures 1C
and 3A). In contrast, Gln98 and Ala99 are pushed fixed and is neither dependent upon the neighboring
residues nor the bound antigen. In the unliganded LC13away by 3–4 A˚ to avoid steric clashes with the
FLRGRAYGL peptide (Figure 3A). crystal structure, it was notable that CDR1 and CDR2
adopted novel canonical forms. Significantly, the move-In contrast to the changes in CDR3, CDR3 is de-
formed and pushed away from the peptide in the li- ments of these two loops are not confined to a rigid
body movement (Figure 3D), with the CDR2 loop under-ganded complex (Figures 3A and 3C). In the unliganded
LC13 TCR, CDR3 points downward, displaying a large going a complete disruption of canonicity. Within CDR1,
there is a rigid body shift (residues 28–32, 1.9 A˚ shift, 16.6degree of mobility (Figure 3A, gray), and is unusual in
that it makes no contacts with the CDR1 loop (Figure rotation) as well as a local “crumple zone” involving
residues 23–27, where Thr26 moves by approximately3C and Kjer-Nielsen et al., 2002b). In the liganded state,
this loop crumples at the hinge point of Pro93 and 7.5 A˚ relative to the unliganded structure (Figures 3E
and 3F).Leu104 (Figure 3A, yellow), allowing residues 96–100,
which are unique to J52, to make extensive contacts Upon binding, CDR1 sits more centrally within the
TCR binding site (Figure 3C), simultaneously increasingwith HLA-B8 by running along its 1 helix (Figures 1C
and 3C). The CDR3 loop residues Ala95 and Gly96 now its contacts with CDR3 (Figure 3C) and reducing inter-
action with CDR2 (Figure 3D). The region that under-interact with CDR1 residues Asp30 and Thr30 (Figure
3C), which in turn leads to formation of specificity con- goes the rigid-body shift abuts the HLA-B8 2 helix,
with side chains in this loop changing conformation totacts between CDR1 Ser28 and the HLA-B8 1-helix
residue Arg62, and CDR1 Thr30 with the 2 helix resi- maximize their collective contacts with HLA-B8 (Figures
1B and 3F).due Gln155 (Figure 3C and Table 2). This conformational
change results in movements of up to 8 A˚ at the tip The CDR2 loop undergoes a very large deformation
upon binding with Ser52 shifting 7 A˚ to point in theof the CDR3 and represents a region of total plastic
deformation rather than a rigid body shift. This move- opposite direction relative to the unliganded state and
adopting a similar location to that previously occupiedment of CDR3 is only possible because the small side
chain of P4 Gly in the FLRGRAYGL peptide offers no by Thr51 in the unliganded structure. Thr51 now folds
back into the cavity, close to where the guanadiniumsteric resistance (Figure 3C). This observation explains
the poor tolerance of other amino acids at P4 in the fine group of Arg70 resides. In addition, Asn54 is in a signifi-
cantly different position (compare Figures 3E and 3F).specificity analysis of LC13 recognition (Figure 2C) and
indicates that the deformation of the CDR3 loop and In an analogous manner to the CDR1 loop, these
changes in the CDR2 loop cannot be wholly attributedthe resultant CDR1 interactions are essential elements
peptide are also shown in green and include the P7 Tyr side chain. The residues in CDR3 and CDR1 that interact upon receptor ligation
are shown. The specificity contacts between CDR1 (Ser28 and Thr30) and HLA-B8 (Arg62 and Gln155) are also indicated.
(D) The CDR1, CDR2, CDR3, and CDR3 loops undergo conformational changes upon binding. The structure is color coded with the
uncomplexed conformation shown in orange and the complexed in cyan; CDR loops, or portions of loops, undergoing rigid body movement
upon complexation are shown as light pink (uncomplexed) and magenta (complexed). Similarly, CDR loops, or portions of loops, undergoing
non-rigid body movements upon complexation are shown as light gray (uncomplexed) and dark gray (complexed). The movement of CDR1
toward CDR3 is evident in the complexed state.
(E) Conformation of the CDR1 and CDR2 loops in the unliganded state.
(F) Conformation of the CDR1 and CDR2 loops in the liganded state. Disruption of the canonical structure of the CDR1 (light pink) and
CDR2 (light blue) loops involves altered interactions with the TCR HV4 residue Arg70 (yellow).
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to its direct interaction with HLA-B8/FLRGRAYGL (Table
2). However, Arg70 within the HV4 loop is a residue
that links CDR1 and CDR2 and is seen to change
conformation between the two states (compare Figures
3E and 3F). In the unliganded structure, the CDR1 loop
packs in a parallel manner against the Arg70 side
chain—a unique interaction that has not previously been
seen in other TCR crystal structures (Figure 3E). In the
complexed state, Arg70 points toward the CDR1 loop,
but the hydrogen-bonding interactions with the guana-
dinium group (Ser28O and Leu50O) are maintained
(Figure 3F). Thus it appears that upon binding, the Arg70
drags and forces the CDR1 and CDR2 loops to adopt
a novel conformation.
The dramatic conformational changes at the LC13
interface are in contrast to those observed in the 2C
and the KB5-C20 system, where non-rigid body confor-
mational change was restricted to the CDR3 loops. This
segmental restriction of CDR1/2 movement in other
TCRs is largely analogous to that observed in antibody-
antigen interactions. Accordingly, the canonicity-gov-
erning rules derived for antibodies are not wholly appli-
cable for the unliganded and liganded forms of the LC13
immunodominant receptor, and it will be of interest to
determine whether this observation may be extended
to other TCR systems.
Ligand-Induced Conformational Changes in C at the
Putative Interface with the Signaling Molecule CD3
Upon ligation of the TCR, a signal is conveyed to the T
cell by an unknown mechanism. Signaling is carried out
by the CD3 components, CD3, -, -, or -, through
immunoreceptor tyrosine-based activation motifs (Sun
et al., 2001). Recent evidence suggests that the TCR-
CD3 complex undergoes a ligand-induced conforma-
tional change that recruits the adaptor protein Nck to
the cytoplasmic tail of CD3 and initiates reorganization
of the actin cytoskeleton (Gil et al., 2002). Significantly,
upon ligation of LC13, there is a conformational move-
ment of the A-B loop of the C domain, as well as
conformational changes in other neighboring loops, that
form the boundary of a cavity thought to accommodate
the CD3 domain from a CD3 heterodimer (Figure 4A).
This conformational change is not the result of crystal
packing since the C domain A-B loop of LC13 is free Figure 4. Conformational Change in the CDomain that May Relate
of crystal contacts in both the unliganded and the com- to a Conformational Switch for Intracellular Signaling in T Cells
plexed form. In contrast to LC13, this region of the 2C (A) The acidic ectodomain of CD3 has been proposed to interact
with the exposed electropositive surface of the A, B, E, and D strandsTCR is involved in extensive crystal contacts which
of the C domain shown in light green (Ghendler et al., 1998; Suncould explain why both the liganded and unliganded
et al., 2001; Wang et al., 1998). This cavity is bordered by the F-Gconformations of C in the 2C TCR resemble the com-
loop of the C domain. Conformational changes between unli-
plexed form of LC13 (Figure 4B) (Garcia et al., 1998, ganded (cyan) and liganded (red) states of this region are shown.
1996). The A-B loop of the N15 TCR structure resembles Positively charged side chains (K121, K132, K136, K184, R190, and
that of the 2C system, and this potentially argues against R230) projecting from C and C are thought to further stabilize the
docking of CD3 into this cavity (Sun et al., 2001). C Lys132 swingsa generalized mode of ligand-induced conformational
toward the cavity upon ligation of LC13 while the whole of the A-Bchange similar to that observed in the LC13 TCR com-
loop shifts to enlarge the cavity in the liganded complex.plex (Wang et al., 1998). However, N15 is liganded to a
(B) Comparison of A-B loop structure in a number of different TCRs.
Fab fragment of a mAb that recognizes the F-G loop of Color coding of the A-B loop is as follows: unliganded LC13, cyan;
C which may affect the conformation of the C A-B liganded LC13, red; 2C, blue; A6 weak agonist, green; and the par-
loop. On the other hand, in the B7 TCR complexed with tially built loop of the B7 TCR, orange. The N15 A-B loop structure
is not shown but resembles the 2C structure.HLA-A2/Tax, the C domain A-B loop is free of crystal
contacts, and although it is only partially built it resem-
bles the conformation of the complexed LC13 (pdb code
1bd2) (Ding et al., 1998; Garboczi et al., 1996). In con-
Structural Basis of T Cell Receptor Immunodominance
61
trast, in the structures of the A6 TCR complexed with residues that make particular structural contributions to
specificity include the five CDR2 residues that interactantagonist and weak agonist ligands of the HLA-A2/Tax
with the HLA-B8 1 helix and are unique to TRBV 7-8complex, the C A-B loops resemble the structure in
and 7-9 (Tyr48, Gln50, Asn51, Glu52, Leu55) and thethe uncomplexed LC13 (pdb codes 1qrn, 1qse, 1qsf)
J7-2 residue Tyr100 that interacts with the peptide(Ding et al., 1999) (Figure 4B). Therefore it is quite possi-
residues P6 Gly and P7 Tyr and is found in only one otherble that the ligand-induced change seen in the LC13 C
germline J segment. Non-germline TCR sequencesA-B loop is related to a general mechanism for transmit-
encoded by N-region remodeling of one of the D seg-ting ligand signals to T cells and that the magnitude or
ments also play a crucial role in specificity throughnature of this conformational change could be related to
Gln98, that interacts extensively with the HLA-B8 1the qualitative outcome of TCR ligation, such as agonist
helix and two peptide residues; and Gly97 and Ala99versus antagonist signaling.
that provide important flexibility in this region of theThe negatively charged ectodomain of CD3 is pro-
receptor. Taken together, the structural contributions ofposed to interact with an exposed electropositive sur-
the highly selected genetic components of both TCRface of the A, B, E, and D strands of the C domain
and  all appear intimately involved in obligatory speci-(shown in green in Figure 4A) that is overhung by the
ficity roles. Although other reasons for the dominanthighly conserved 13 amino acid F-G loop peculiar to the
selection of this or other receptors cannot be excluded,C domain (Ghendler et al., 1998; Sun et al., 2001; Wang
they seem unlikely in the case of LC13. The LC13 clono-et al., 1998). Positively charged side chains projecting
type could theoretically result from biased gene re-from C are thought to further stabilize the docking of
arrangements or preferential thymic positive selection.CD3 into this cavity (Sun et al., 2001). One of these
However, the preimmune repertoire in HLA-B8, EBV-residues, C Lys132, swings toward the cavity upon
seronegative donors did not contain a detectable expan-ligation of LC13 while the whole of the A-B loop shifts
sion of the LC13 clonotype when examined by a PCRto enlarge the cavity in the liganded complex (Figure
assay designed to specifically detect clonotypic CDR34). Although crystal structures cannot fully reflect the
sequences (Argaet et al., 1994; Burrows et al., 1995). Thisdynamic alterations that occur upon protein-protein in-
finding concurs with the inability to detect functionalteraction, the ligand-induced conformational adjust-
cytotoxic T lymphocyte precursor cells with specificityment in the A-B loop of C is suggestive of a pro-
for FLRGRAYGL in the same donor group despite thegrammed adjustment at the CD3 interface that might
sensitivity of these assays being better than 1 in 100,000facilitate a “piston-type displacement” of CD3 (Sun
(data not shown). Another possibility is that the diver-et al., 2001) and lead to Nck recruitment (Gil et al., 2002).
sity of receptors capable of interacting with HLA-B8/The arrangement of the other CD3 components is un-
FLRGRAYGL is restricted by self-tolerance or by aclear; however, an extensive electronegative patch lo-
“hole” in the genetic repertoire so that the LC13-likecated on the surface of the C domain may interact with
sequences comprise the prevailing combinations. Thisthe highly basic CD3 subunit (Kjer-Nielsen et al., 2002b)
is not likely because the LC13 clonotype recognizesor with the CD3 heterodimer (Gil et al., 2002; Kjer-
HLA-B44 as an alloantigen (Burrows et al., 1994) and inNielsen et al., 2002b). This idea is supported by the
HLA-B8/B44 heterozygotes, where self-tolerance pre-reactivity of the anti-TCR mAb H28-710 that only recog-
vents use of the LC13 clonotype, the HLA-B8-restricted,nizes this part of the murine C in the absence of CD3
FLRGRAYGL-specific CTL response remains immuno-components (Karaivanova et al., 1999). Additional struc-
dominant in EBV infection (Burrows et al., 1997a, 1995).tures of TCRs in their unliganded and liganded state will
However, instead of using LC13 clonotypes, HLA-B8/be necessary to ascertain a general correlation between
B44 heterozygotes use other TCR combinations to me-C conformation and TCR ligation.
diate recognition of HLA-B8/FLRGRAYGL, with only a
slight fall in precursor T cells of this specificity (Burrows
Discussion et al., 1997b, 1995). This finding demonstrates that the
T cell repertoire contains many potential receptors with
The structure of LC13 complexed to its cognate ligand appropriate specificity for HLA-B8/FLRGRAYGL.
HLA-B8/FLRGRAYGL provides a clear role for the highly Taken together, the data suggest that dominant selec-
selected public components of LC13 in conferring ex- tion of the LC13 clonotype results from its highly refined
quisite receptor specificity. Residues from each of the specificity that must impart preferential antigen-depen-
highly selected V, (D), J, and N-region components of dent expansion of these CTL. The specificity advantage
the TCR and  genes are either directly or indirectly of LC13 may not correlate simply with the affinity of the
crucial to shaping the antigen specificity of the receptor. TCR for cognate ligand. The estimated Kd of LC13 is
In V, these include a combination of four germline- unremarkable at 1  10
5 M (Ely et al., unpublished
encoded residues unique to TRAV26-2 (Ser28, Gly29, data); however, the relationship between TCR/MHCp
Thr30, and Tyr31) that mediate contacts between CDR1 affinity and T cell function can be subtle (Alam et al.,
and the HLA-B8 1 and 2 helices; the unique V frame- 1999). Moreover, we have not detected any dose re-
work residue His48 that along with CDR1 Tyr31 medi- sponse advantage of LC13 CTL in peptide titration com-
ates critical bonding with P7 Tyr of the FLRGRAYGL parisons with other CTL of the same specificity (data
peptide; the germline-encoded segment comprising not shown). Therefore the specificity advantage of this
residues 96–100 that is unique to J52 and interacts clonotype presumably manifests in some other aspect
extensively with the HLA-B8 1 helix; and the J52 resi- of T cell activation, perhaps involving superior functional
due Leu104 that, along with the N-region residue Pro93, avidity of the naive T cells, better signaling upon ligation,
or more efficient formation of the supramolecular com-is a hinge point for the crumpling of CDR3. In V, the
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2.5 A˚ model, which comprises residues 1–277 (hc), 1–99 (2M), 1–9plex formed during induction and maintenance of the
(peptide), 2–206 ( chain), 3–247 ( chain), and 255 water molecules,immune response. It is an intriguing possibility that the
has an Rfac of 22.6% and Rfree of 28.8%, respectively (see Table 1LC13 clonotype may gain a selective advantage through
for statistics). Simulated annealing omit maps were used to carefully
superior transmission of signals related to the ligand- validate the conformational changes that occurred upon complex-
induced conformational change observed in the putative ation.
C docking site for CD3. All these possibilities are
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